A Phase 2/3 interventional study of Amisulpride Injection and Dexamethasone in Nausea and Vomiting, Postoperative, sponsored by Acacia Pharma Ltd. Completed at 14 sites in 4 countries. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Acacia Pharma Ltd · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing amisulpride in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Amisulpride · Postoperative Nausea and Vomiting.
Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, this one is the 6th largest by enrollment, is the only one that started in 2024, is the only one in phase 2/3, and was the 8th registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →2 of the 11 studies testing amisulpride in Postoperative Nausea and Vomiting are open now, in 1 country. Recruiting first, the newest first:
Qianfoshan Hospital
Ages 18–75
Sir Run Run Shaw Hospital · Sites in China
Ages 18–65 · Women only
By country, each count listing its studies:
Amisulpride: first FDA approval 2020 (BARHEMSYS). What it is approved for, and how studies give it, is on its page →
Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.
This study: 2 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Median enrollment 453 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
Acacia Pharma Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.
10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd: none open now, none under way, none of them phase 3. Of 9 finished, 7 (78%) have results posted.
Among the 10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd, this one is the only one that started in 2024, is the only one in phase 2/3, and was the 10th registered.
Acacia Pharma Ltd’s Postoperative Nausea and Vomiting studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, from their registry updates:
Among Acacia Pharma Ltd’s 10 in Postoperative Nausea and Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting
Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone
Drug: Amisulpride Injection · Drug: Dexamethasone
Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone
Drug: Amisulpride Injection · Drug: Dexamethasone
Dose finding treatment for continuation to phase 3
Also known as: Barhemsys
Standard of care treatment
Also known as: Decadron
Evaluate Complete Response
Defined as no vomiting/retching (absence of PONV) and no use of anti-emetic rescue medication, during the first 24 hours after completion of surgery. Subjects will be questioned and assessed.
Time frame: 1 Day
Occurrence of post-operative vomiting/retching
Subjects considered able to understand and provide a meaningful response should be asked if they have nausea ("feel sick" or other equivalent words) at the following times after completion of surgery (wound closure), unless an episode of PONV or discharge of the subject from the site has already occurred prior to the time point: 1 hour, 2 hours, 6 hours and 24 hours or when they first vomit, retch or receive rescue medication. In subjects aged ≥ 6 years, at the above time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.
Time frame: 1 Day
Use of rescue medication
Document use of rescue medication.
Time frame: 1 Day
Occurrence and severity of post-operative nausea
An episode of nausea should be recorded any time that a subject spontaneously complains of nausea (including a request for rescue medication due to nausea). Subjects considered able to understand and provide a meaningful response should be asked if they have nausea ("feel sick" or other equivalent words) at the following times after completion of surgery (wound closure), unless an episode of PONV or discharge of the subject from the site has already occurred prior to the time point: 1 hour, 2 hours, 6 hours and 24 hours or when they first vomit, retch or receive rescue medication. In subjects aged ≥ 6 years, at the above time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.
Time frame: 1 Day
Time to emergence of PONV
Observe for, question and document emergence of vomiting/retching and nausea. In subjects aged ≥ 6 years, at specified time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.
Time frame: 1 Day
Time to emergence of vomiting/retching, significant nausea, and rescue medication, individually
Observe for emergence of vomiting/retching, determine significance of nausea, and note rescue medication, individually.
Time frame: 1 Day
Different variables during different time ranges after the end of surgery (0-2 h, 2-6 h and 6-24 h)
Subjects considered able to understand and provide a meaningful response should be asked if they have nausea ("feel sick" or other equivalent words) at the following times after completion of surgery (wound closure), unless an episode of PONV or discharge of the subject from the site has already occurred prior to the time point: 1 hour, 2 hours, 6 hours and 24 hours or when they first vomit, retch or receive rescue medication. In subjects aged ≥ 6 years, at the above time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.
Time frame: 1 Day
The above variables in the sub-groups of patients who did and did not receive opioid analgesia
Concomitant medications will be reviewed.
Time frame: 1 Day
Safety: The nature and frequency of adverse events and laboratory and electrocardiography (ECG) abnormalities
Adverse events, laboratory and ECG abnormalities will be noted. Blood samples should be drawn at screening (unless recent pre-existing results are available) and again post-operatively, as soon as practically possible after the patient's entry to the post-anesthesia care unit, recovery room or equivalent, and in any event within 1 hour after the end of surgery. Twelve-lead ECGs will be collected at screening. An ECG already taken as part of medical care within the period of 2 weeks prior to screening may be used to determine eligibility and to provide baseline ECG data. In the peri-/post-operative period, continuous Holter monitoring of the ECG will be performed, from at least 10 minutes prior until at least 2 hours after the start of administration of amisulpride study medication.
Time frame: 7 Days
Key pharmacokinetics parameter - Peak Plasma Concentration
Plasma samples will be drawn as required at specified timepoints to determine the PK profile of peak plasma concentration of amisulpride in subjects.
Time frame: 1 Day
Key pharmacokinetics parameter - Total Exposure
Plasma samples will be drawn as required at specified timepoints to determine the PK profile of total exposure of amisulpride in subjects.
Time frame: 1 Day
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Jun 2025, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amisulpride
Postoperative Nausea and Vomiting →
Acacia Pharma Ltd